FDA Brief

Warning letters Devices

FDA warning letter to

Unilam Co., LTD

High riskIssued Sep 22Posted Oct 6Center for Devices and Radiological Health

Unilam Co., LTD's UV sunlamps violate quality-system and radiation-safety testing rules, FDA says.

What happened

FDA inspected Unilam's facility in Ulju-gun, Ulsan, South Korea, from 05/18/2026 through 05/22/2026 and found its SUV 600-800/KT/GYU UV Sunlamp adulterated under the Quality System regulation. FDA also determined the sunlamps fail federal electronic product radiation control requirements, citing inadequate risk management, design validation, supplier controls, calibration, sampling, and certification-testing documentation.

What FDA found

  1. Unilam lacked an adequate design risk-management process; its design risk analysis covered only four items and did not address foreseeable risks such as chemical exposure if a lamp breaks.

    ISO 13485:2016 Clause 7.1; 21 CFR Part 820
  2. Design validation and change control were inadequately documented, including no UVC emission results over the full 800-hour expected lifetime and no clear design-control procedure.

    ISO 13485:2016 Clause 7.3.1; 21 CFR Part 820
  3. Supplier evaluation and selection criteria were inadequate, and a quartz-tube supplier evaluation was contradictory, marked "Not Registered" at the minimum passing score.

    ISO 13485:2016 Clause 7.4.1
  4. Unilam lacked written agreements requiring quartz-tube, mercury, and krypton suppliers to notify it of changes before implementation.

    ISO 13485:2016 Clause 7.4.2
  5. Calibration and monitoring procedures for the integrating sphere did not cover the UVC/UVB ranges used and did not adequately requalify the equipment after a 2021 fire.

    ISO 13485:2016 Clause 7.6
  6. Certification testing and sampling lacked documented statistical basis, measurement details, aging evidence, and worst-case justification needed to show compliance with the sunlamp performance standard.

    21 CFR 1040.20(f); 21 CFR 1010.2; ISO 13485:2016 Clause 8.2.6

What FDA wants

FDA asks Unilam to respond in writing within 15 business days with steps to correct the violations, prevent recurrence, and provide the requested radiation-testing documentation, including measurement details, aging evidence, worst-case justification, and sampling-plan validation. If actions will take longer, the company must include a timetable.

Who should pay attention

  • US importers and distributors of UV sunlamps
  • sunlamp bed manufacturers that rely on these lamps
  • medical-device quality teams handling supplier and design controls

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. USV Private Limited

    FDA warned USV Private Limited that its sterile injectable manufacturing in Daman, India, had aseptic-processing, facility-design and visible-particulate violations.

    High risk
  2. Peter Schiff Enterprises

    FDA warns Peter Schiff Enterprises over unapproved cardiac devices and serious quality system failures.

    High risk
  3. Chirp Innovations, LLC

    FDA warned Chirp Innovations over quality-system gaps, missing adverse-event reporting procedures, and unapproved marketing of its Halo muscle stimulator for menstrual pain.

    High risk
  4. Pro-Optics, LLC

    FDA warned Pro-Optics about unapproved material and color changes to contact lens cases and quality system failures.

    Medium